KH607 / Chengdu Kanghong Pharma - LARVOL DELTA

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum Depression (clinicaltrials.gov) - P2 | N=72 | Not yet recruiting | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.

New P2 trial • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.

New P2 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

The Discovery and Development of KH607 as a Treatment for Postpartum Depression (PPD) and Major Depressive Disorder (MDD) (APA 2025) - "Phase II clinical studies are currently ongoing. We expect that the compound to be developed as a new treatment to address the unmet medical needs for PPD and MDD patients."

CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Postpartum Depression • Psychiatry

Phase 1 Study of KH607 Tablets (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.

New P1 trial